Hepion Pharmaceuticals updates CRV431 liver program, shares follow biotech peers

Hepion Pharmaceuticals refines its CRV431 liver disease development path as biotech peers show mixed sentiment. The micro-cap Nasdaq biotech highlights its NASH and fibrosis focus while investors watch sector trends and upcoming data catalysts.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 14:24.

Hepion Pharmaceuticals (US4268971032) focuses its clinical development on the liver disease candidate CRV431 while its Nasdaq listing trades in a cautious small-cap biotech segment alongside peers like Intercept Pharmaceuticals and Madrigal Pharmaceuticals. Sector commentary highlights ongoing volatility and selective interest in NASH and fibrosis plays from institutional investors per recent biotech market reviews from sources such as BioCentury and institutional strategy notes.

Where Hepion positions CRV431

Hepion Pharmaceuticals Inc. describes itself as a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases, with its lead candidate CRV431 targeting non-alcoholic steatohepatitis and liver fibrosis as outlined in its latest corporate overview and pipeline materials. The company's investor relations presentation summarizes CRV431's mechanism and indication focus while pointing out the significant unmet medical need in NASH and related fibrotic conditions in the US and globally.

Liver disease-focused biotech names remain under close watch from sector analysts who compare Hepion's strategy to more advanced NASH players such as Madrigal Pharmaceuticals and small-cap fibrosis developers covered in recent rating and sector pieces by houses like Jefferies and Berenberg. Reuters' broader biotech reporting underlines that liver and metabolic pipelines continue to attract deal interest and volatility as larger pharmaceutical groups assess partnering and acquisition options.

Friday focus on biotech sector peers

On this Friday, traders looking at Hepion Pharmaceuticals shares tend to benchmark the micro-cap against other liver and metabolic disease biotechs on Nasdaq, where indices such as the Nasdaq Biotechnology Index reflect sentiment toward higher-risk clinical-stage stories. Sector recap pieces on platforms like Yahoo Finance and MarketWatch describe how newsflow from better-known names in oncology and metabolic disease can influence smaller developers' trading patterns via ETF flows and relative-value positioning. Yahoo Finance's biotech coverage mentions mixed performance across clinical-stage names as investors sift through trial updates and financing plans.

Analyst commentary on small biotechnology groups frequently highlights key factors such as cash runway, clarity of upcoming trial milestones, and partnering optionality, criteria that also frame investor views on Hepion Pharmaceuticals. While coverage depth for Hepion itself is limited compared with larger peers, institutional notes on liver disease pipelines point to NASH and fibrosis as areas where regulators, including the US Food and Drug Administration, are gradually gaining more experience, which may shape future approval pathways and valuation frameworks for developers like Hepion.

How Hepion aims to make money

Hepion Pharmaceuticals' business model centers on the clinical development and potential commercialization or partnering of CRV431 and other pipeline candidates for liver diseases, with a focus on NASH and viral hepatitis-associated liver injury. The company targets revenue generation via future drug sales, licensing, and collaboration agreements rather than current marketed products, placing it firmly in the high-risk, high-reward clinical-stage category where success depends on achieving positive trial outcomes and regulatory approvals.

Where the stock trades today

Hepion Pharmaceuticals stock trades on Nasdaq in US dollars, with the latest available quote showing the shares around the 0.30 USD area as of 2026-06-26, 12:20, reflecting its micro-cap biotech status and the volatility typical for companies in early-stage liver disease drug development.

Hepion Pharmaceuticals at a glance

• Company: Hepion Pharmaceuticals Inc.
• ISIN: US4268971032
• WKN: A2PF52
• Ticker: HEPA
• Trading venue: Nasdaq
• Price (as of 2026-06-26, 12:20): 0.30 USD
• Market cap: roughly 25 million USD (as of 2026-06-26)
• Sector / industry: Biotechnology - liver disease therapeutics
• Index membership: None of the major headline indices; trades as a micro-cap biotech on Nasdaq
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.